Short-term outcomes in patients with acute coronary syndrome treated with direct bioresorbable scaffold deployment

Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):381-5. doi: 10.1016/j.carrev.2015.06.007. Epub 2015 Jul 9.

Abstract

Background: Direct coronary stenting is a validated therapeutic option for coronary lesions. We studied the feasibility of direct deployment with a bioresorbable vascular scaffold (BVS) in acute coronary syndrome (ACS).

Methods: Demographic, procedural, and survival data were obtained for patients who had direct scaffold deployment with BVS from 1 May 2013 to 1 April 2014.

Results: We performed a retrospective review of nine patients which included eight patients having ST-elevation myocardial infarction. There were no cases of worsening coronary flow, scaffold thrombosis, target lesion revascularization or death up to 30 days post intervention.

Conclusion: Direct BVS deployment in ACS appears safe and feasible.

Keywords: Bioresorbable vascular scaffold; Direct coronary stenting; Myocardial infarction.

MeSH terms

  • Absorbable Implants*
  • Academic Medical Centers
  • Acute Coronary Syndrome / diagnosis
  • Acute Coronary Syndrome / mortality
  • Acute Coronary Syndrome / physiopathology
  • Acute Coronary Syndrome / therapy*
  • Adult
  • Aged
  • Coronary Angiography
  • Coronary Circulation
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Microcirculation
  • Middle Aged
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / mortality
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Ontario
  • Percutaneous Coronary Intervention / adverse effects
  • Percutaneous Coronary Intervention / instrumentation*
  • Prosthesis Design
  • Retrospective Studies
  • Tertiary Care Centers
  • Time Factors
  • Tomography, Optical Coherence
  • Treatment Outcome